News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
康哲藥業(00867.HK)自主研發INHBE小核酸藥物CMS-D008亮相ADA大會
康哲藥業(00867.HK)宣佈，其自主研發的創新藥INHBE小核酸藥物CMS-D008注射液「CMS-D008」的臨床前結果在第86屆美國糖尿病協會(ADA)大會以壁報形式發佈。ADA大會作為全球糖尿病及代謝疾病領域規模最大、最具權威影響力的年度學術風向標，此次匯聚了來自世界各地的超過12,000名頂尖臨床專家、科研學者及一線醫療工作者，共同探討與見證前沿...
Reset
Send
The window will close in 5 seconds
康哲藥業(00867.HK)自主研發INHBE小核酸藥物CMS-D008亮相ADA大會
Close
Recommend
2
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

康哲藥業(00867.HK)  +0.180 (+1.664%)    Short selling $29.01M; Ratio 36.265%   宣佈，其自主研發的創新藥INHBE小核酸藥物CMS-D008注射液「CMS-D008」的臨床前結果在第86屆美國糖尿病協會(ADA)大會以壁報形式發佈。ADA大會作為全球糖尿病及代謝疾病領域規模最大、最具權威影響力的年度學術風向標，此次匯聚了來自世界各地的超過12,000名頂尖臨床專家、科研學者及一線醫療工作者，共同探討與見證前沿診療成果與技術創新突破。

CMS-D008展現出令人鼓舞的非臨床數據。本次在ADA大會發表CMS-D008的臨床前研究結果顯示，在肥胖動物模型中，CMS-D008可高效持續抑制INHBE表達，在不影響肌肉的情況下，獲得明顯的減重減脂效果，且安全性良好，有望實現健康減重。(su/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-12 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.